Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.

Ghazal S, Ridha Z, D'Aguanno K, Nassim D, Quaiattini A, Netchiporouk E, Poulin Y, Kalia S, Marcoux D, Piguet V, Jack C

Open source

DOI
10.3389/fmed.2022.821871
Published
2022
Container
Frontiers in medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2022.821871,
  title = {Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.},
  author = {Ghazal S and Ridha Z and D'Aguanno K and Nassim D and Quaiattini A and Netchiporouk E and Poulin Y and Kalia S and Marcoux D and Piguet V and Jack C},
  year = {2022},
  journal = {Frontiers in medicine},
  doi = {10.3389/fmed.2022.821871},
  url = {https://doi.org/10.3389/fmed.2022.821871}
}

RIS

TY  - JOUR
TI  - Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.
AU  - Ghazal S
AU  - Ridha Z
AU  - D'Aguanno K
AU  - Nassim D
AU  - Quaiattini A
AU  - Netchiporouk E
AU  - Poulin Y
AU  - Kalia S
AU  - Marcoux D
AU  - Piguet V
AU  - Jack C
PY  - 2022
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2022.821871
UR  - https://doi.org/10.3389/fmed.2022.821871
ER  - 

APA

S, G., Z, R., K, D., D, N., A, Q., E, N., Y, P., S, K., D, M., V, P., & C, J. (2022). Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.. Frontiers in medicine. https://doi.org/10.3389/fmed.2022.821871

Source records